By Dr. James Partyka | PHARMATIVE August 6, 2022 Here’s a brief COVID-19 pandemic update in the United States: Unfortunately daily COVID-19 cases are increasing in the United States largely due to the...
One person treated with a broadly neutralizing antibody plus romidepsin remained in remission for 3.7 years. By Liz Highleyman | POZ via Pride Nation One individual treated with the broadly neutralizi...
IAPAC president and CEO José M. Zuniga, PhD, MPH, reflects on the current humanitarian crisis in Ukraine and how you can help. By Jienna Foster | POZ via PrideNation Over the past four weeks, Ukraine ...
Medically Reviewed by Melinda Ratini, DO, MS | WebMd via PrideNation Take a Pill, Protect Your Memory? 1/13 “Improves memory.” “Sharpens focus.” These are just some of the clai...
The experimental vaccine regimen aims to train B cells to produce broadly neutralizing antibodies against HIV. By Liz Highleyman | POZ via PHARMATIVE The first doses of an experimental HIV vaccin...
By Kristie Overstreet, PhD | mbg via PHARMATIVE When was the last time you felt connected with your partner? That feeling of safety and security in your relationship? If it’s been a while, know ...
COVID-19, HIV vaccine and cure news, and long-acting HIV treatment and prevention topped the news again this year. By Liz Highleyman and Ian Anderson | POZ via PHARMATIVE In the second year of the pan...
By Sandra Lopez-Leon et al. | Nature via PHARMATIVE Abstract COVID-19 can involve persistence, sequelae, and other medical complications that last weeks to months after initial recovery. This systemat...
By Kathy Katella | Yale Medicine via PHARMATIVE Yale Medicine doctors answer common questions about Merck’s new COVID-19 treatment. Over the past year, discussions—sometimes heated ones—about ending t...